JP2018510195A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018510195A5 JP2018510195A5 JP2017551650A JP2017551650A JP2018510195A5 JP 2018510195 A5 JP2018510195 A5 JP 2018510195A5 JP 2017551650 A JP2017551650 A JP 2017551650A JP 2017551650 A JP2017551650 A JP 2017551650A JP 2018510195 A5 JP2018510195 A5 JP 2018510195A5
- Authority
- JP
- Japan
- Prior art keywords
- milbemycin
- avermectin
- parasite
- cyclooctadepsipeptide
- mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 50
- 239000005660 Abamectin Substances 0.000 claims description 22
- 244000045947 parasite Species 0.000 claims description 19
- FXWHFKOXMBTCMP-WMEDONTMSA-N milbemycin Natural products COC1C2OCC3=C/C=C/C(C)CC(=CCC4CC(CC5(O4)OC(C)C(C)C(OC(=O)C(C)CC(C)C)C5O)OC(=O)C(C=C1C)C23O)C FXWHFKOXMBTCMP-WMEDONTMSA-N 0.000 claims description 15
- 241000124008 Mammalia Species 0.000 claims description 14
- 208000030852 Parasitic disease Diseases 0.000 claims description 14
- RRZXIRBKKLTSOM-XPNPUAGNSA-N avermectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 RRZXIRBKKLTSOM-XPNPUAGNSA-N 0.000 claims description 14
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 claims description 12
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 claims description 12
- 229960002418 ivermectin Drugs 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 9
- YJNUXGPXJFAUQJ-LYWANRAQSA-N PF1022A Chemical compound C([C@@H]1C(=O)N(C)[C@H](C(O[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@H](CC=2C=CC=CC=2)C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)O1)=O)CC(C)C)C1=CC=CC=C1 YJNUXGPXJFAUQJ-LYWANRAQSA-N 0.000 claims description 8
- -1 latidectin Chemical compound 0.000 claims description 8
- IBSREHMXUMOFBB-JFUDTMANSA-N 5u8924t11h Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 IBSREHMXUMOFBB-JFUDTMANSA-N 0.000 claims description 7
- 239000005894 Emamectin Substances 0.000 claims description 7
- 229950008167 abamectin Drugs 0.000 claims description 7
- CXEGAUYXQAKHKJ-NSBHKLITSA-N emamectin B1a Chemical compound C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](NC)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 CXEGAUYXQAKHKJ-NSBHKLITSA-N 0.000 claims description 7
- WPNHOHPRXXCPRA-TVXIRPTOSA-N eprinomectin Chemical compound O1[C@@H](C)[C@@H](NC(C)=O)[C@H](OC)C[C@@H]1O[C@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C\C=C/[C@@H]2C)\C)O[C@H]1C WPNHOHPRXXCPRA-TVXIRPTOSA-N 0.000 claims description 7
- 229960002346 eprinomectin Drugs 0.000 claims description 7
- HICUREFSAIZXFQ-JOWPUVSESA-N i9z29i000j Chemical compound C1C[C@H](C)[C@@H](CC)O[C@@]21O[C@H](C\C=C(C)\[C@H](OC(=O)C(=N/OC)\C=1C=CC=CC=1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 HICUREFSAIZXFQ-JOWPUVSESA-N 0.000 claims description 7
- CKVMAPHTVCTEMM-ALPQRHTBSA-N milbemycin oxime Chemical compound O1[C@H](C)[C@@H](C)CC[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)C(=N/O)/[C@H]3OC\2)O)C[C@H]4C1.C1C[C@H](C)[C@@H](CC)O[C@@]21O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)C(=N/O)/[C@H]3OC\1)O)C[C@H]4C2 CKVMAPHTVCTEMM-ALPQRHTBSA-N 0.000 claims description 7
- 229940099245 milbemycin oxime Drugs 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- YZBLFMPOMVTDJY-CBYMMZEQSA-N moxidectin Chemical compound O1[C@H](C(\C)=C\C(C)C)[C@@H](C)C(=N/OC)\C[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 YZBLFMPOMVTDJY-CBYMMZEQSA-N 0.000 claims description 7
- 229960004816 moxidectin Drugs 0.000 claims description 7
- AFJYYKSVHJGXSN-KAJWKRCWSA-N selamectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1C(/C)=C/C[C@@H](O[C@]2(O[C@@H]([C@@H](C)CC2)C2CCCCC2)C2)C[C@@H]2OC(=O)[C@@H]([C@]23O)C=C(C)C(=N\O)/[C@H]3OC\C2=C/C=C/[C@@H]1C AFJYYKSVHJGXSN-KAJWKRCWSA-N 0.000 claims description 7
- 229960002245 selamectin Drugs 0.000 claims description 7
- 241000243990 Dirofilaria Species 0.000 claims description 6
- CMZOLQQGUABKKN-STGYROPVSA-N dimadectin Chemical compound O([C@H]1C[C@@H](C2)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C\C=C/[C@H](C)[C@@H](C(=C/C1)\C)OCOCCOC)[C@]12CC[C@H](C)[C@@H](C(C)C)O1 CMZOLQQGUABKKN-STGYROPVSA-N 0.000 claims description 6
- 229950004439 dimadectin Drugs 0.000 claims description 6
- QLFZZSKTJWDQOS-YDBLARSUSA-N doramectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C3CCCCC3)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C QLFZZSKTJWDQOS-YDBLARSUSA-N 0.000 claims description 6
- 229960003997 doramectin Drugs 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 108010004210 PF 1022A Proteins 0.000 claims description 5
- 108010056417 emodepside Proteins 0.000 claims description 5
- ZMQMTKVVAMWKNY-YSXLEBCMSA-N emodepside Chemical group C([C@@H]1C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@H](C)C(=O)N(C)[C@H](C(O[C@H](CC=2C=CC(=CC=2)N2CCOCC2)C(=O)N(C)[C@@H](CC(C)C)C(=O)O[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)O1)=O)CC(C)C)C(C=C1)=CC=C1N1CCOCC1 ZMQMTKVVAMWKNY-YSXLEBCMSA-N 0.000 claims description 5
- 229960001575 emodepside Drugs 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000001747 exhibiting effect Effects 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000004540 pour-on Substances 0.000 claims description 2
- 208000023504 respiratory system disease Diseases 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 230000002195 synergetic effect Effects 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 1
- 229950000961 latidectin Drugs 0.000 claims 1
- 150000002596 lactones Chemical class 0.000 description 14
- 108010002156 Depsipeptides Proteins 0.000 description 11
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- FSVJFNAIGNNGKK-UHFFFAOYSA-N 2-[cyclohexyl(oxo)methyl]-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one Chemical compound C1C(C2=CC=CC=C2CC2)N2C(=O)CN1C(=O)C1CCCCC1 FSVJFNAIGNNGKK-UHFFFAOYSA-N 0.000 description 2
- 229960002957 praziquantel Drugs 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- LGUDKOQUWIHXOV-UHFFFAOYSA-N epsiprantel Chemical compound C1C(C2=CC=CC=C2CCC2)N2C(=O)CN1C(=O)C1CCCCC1 LGUDKOQUWIHXOV-UHFFFAOYSA-N 0.000 description 1
- 229960005362 epsiprantel Drugs 0.000 description 1
- 229940052423 profender Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562142304P | 2015-04-02 | 2015-04-02 | |
| US62/142,304 | 2015-04-02 | ||
| PCT/US2016/025714 WO2016161369A1 (en) | 2015-04-02 | 2016-04-01 | Anthelmintic combinations and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018510195A JP2018510195A (ja) | 2018-04-12 |
| JP2018510195A5 true JP2018510195A5 (https=) | 2019-05-09 |
| JP6899330B2 JP6899330B2 (ja) | 2021-07-07 |
Family
ID=57006415
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017551650A Expired - Fee Related JP6899330B2 (ja) | 2015-04-02 | 2016-04-01 | 駆虫剤の組合せ及びその使用方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10993988B2 (https=) |
| EP (1) | EP3277303B1 (https=) |
| JP (1) | JP6899330B2 (https=) |
| KR (1) | KR20170132330A (https=) |
| CN (1) | CN107567334A (https=) |
| AU (1) | AU2016244022A1 (https=) |
| BR (1) | BR112017020975A2 (https=) |
| CA (1) | CA2981489A1 (https=) |
| CL (1) | CL2017002474A1 (https=) |
| CO (1) | CO2017011284A2 (https=) |
| ES (1) | ES2851345T3 (https=) |
| IL (1) | IL254783B (https=) |
| MX (1) | MX381319B (https=) |
| MY (1) | MY187835A (https=) |
| PH (1) | PH12017501806A1 (https=) |
| RU (1) | RU2717545C2 (https=) |
| SG (1) | SG11201708008TA (https=) |
| WO (1) | WO2016161369A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3541789A1 (en) * | 2016-11-16 | 2019-09-25 | Boehringer Ingelheim Animal Health USA Inc. | Anthelmintic depsipeptide compounds |
| PT3579696T (pt) * | 2017-02-08 | 2023-07-19 | Boehringer Ingelheim Animal Health Usa Inc | Modelo in vivo para infeção por vermes parasitários e métodos para avaliação de compostos antiparasíticos, que incluem compostos ativos contra a dirofilariose canina |
| BR112020010291A2 (pt) | 2017-11-23 | 2020-11-17 | Ceva Sante Animale | composição contendo moxidectina para tratamento de infestações de parasitas |
| MX2020005573A (es) * | 2017-11-29 | 2020-09-10 | Zoetis Services Llc | Depsipeptidos endoparasitarios. |
| AR116524A1 (es) * | 2018-10-04 | 2021-05-19 | Elanco Tiergesundheit Ag | Potenciación de tratamiento de helmintos |
| EP4208157A1 (en) | 2020-09-04 | 2023-07-12 | Elanco Us Inc. | Palatable formulations |
| GB202100635D0 (en) * | 2021-01-18 | 2021-03-03 | Liverpool School Tropical Medicine | Compounds and methods for treating or preventing dirofilaria infection in a mammal |
| US11999742B2 (en) | 2021-11-01 | 2024-06-04 | Boehringer Ingelheim Vetmedica Gmbh | Substituted pyrrolo[1,2-b]pyridazines as anthelmintics |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4134973A (en) | 1977-04-11 | 1979-01-16 | Merck & Co., Inc. | Carbohydrate derivatives of milbemycin and processes therefor |
| GB9300883D0 (en) | 1993-01-18 | 1993-03-10 | Pfizer Ltd | Antiparasitic agents |
| DE19520275A1 (de) * | 1995-06-02 | 1996-12-05 | Bayer Ag | Endoparasitizide Mittel |
| US20030129680A1 (en) | 2001-10-31 | 2003-07-10 | O'connor Thomas Patrick | Multi-analyte assay device |
| US20070042354A1 (en) | 2005-08-19 | 2007-02-22 | Engelhard Eric K | Detecting pathogens in companion animals |
| ES2367332T3 (es) * | 2007-02-21 | 2011-11-02 | Pfizer Limited | Agentes antiparasitarios de benzofurano. |
| JP4734656B2 (ja) | 2007-03-30 | 2011-07-27 | 国立大学法人群馬大学 | Ｐｆ１０２２類の製造法 |
| DE102008022520A1 (de) * | 2008-05-07 | 2009-11-12 | Bayer Animal Health Gmbh | Feste Arzneimittelformulierung mit verzögerter Freisetzung |
| US8809268B2 (en) | 2008-10-29 | 2014-08-19 | The Regents Of The University Of California | Combination therapy to combat helminth resistance |
| BE1019407A5 (nl) | 2009-11-06 | 2012-07-03 | Momentum Animal Cure Bvba | Middel voor het uitdrijven van parasieten bij mensen, dieren en vogels. |
| CN102741252A (zh) | 2010-02-05 | 2012-10-17 | 英特维特国际股份有限公司 | 用作驱虫剂的螺吲哚啉化合物 |
| US9758840B2 (en) | 2010-03-14 | 2017-09-12 | Ibis Biosciences, Inc. | Parasite detection via endosymbiont detection |
| RU2452180C2 (ru) | 2010-08-31 | 2012-06-10 | Общество с ограниченной ответственностью "Научно-внедренческое предприятие "Астрафарм" | Комплексная антипаразитарная композиция |
| AU2010249226C1 (en) | 2010-12-08 | 2017-04-13 | Zoetis Services Llc | Anthelmintic formulation |
| AU2010101389C4 (en) | 2010-12-08 | 2017-03-02 | Jurox Pty Ltd | Anthelmintic formulation |
| US9096599B2 (en) | 2011-08-04 | 2015-08-04 | Intervet Inc. | Spiroindoline compounds |
-
2016
- 2016-04-01 CA CA2981489A patent/CA2981489A1/en not_active Abandoned
- 2016-04-01 ES ES16721277T patent/ES2851345T3/es active Active
- 2016-04-01 BR BR112017020975A patent/BR112017020975A2/pt not_active IP Right Cessation
- 2016-04-01 SG SG11201708008TA patent/SG11201708008TA/en unknown
- 2016-04-01 AU AU2016244022A patent/AU2016244022A1/en not_active Abandoned
- 2016-04-01 EP EP16721277.8A patent/EP3277303B1/en active Active
- 2016-04-01 RU RU2017138118A patent/RU2717545C2/ru active
- 2016-04-01 WO PCT/US2016/025714 patent/WO2016161369A1/en not_active Ceased
- 2016-04-01 JP JP2017551650A patent/JP6899330B2/ja not_active Expired - Fee Related
- 2016-04-01 MY MYPI2017001452A patent/MY187835A/en unknown
- 2016-04-01 CN CN201680025471.5A patent/CN107567334A/zh active Pending
- 2016-04-01 KR KR1020177031879A patent/KR20170132330A/ko not_active Withdrawn
- 2016-04-01 US US15/089,282 patent/US10993988B2/en active Active
- 2016-04-01 MX MX2017012510A patent/MX381319B/es unknown
-
2017
- 2017-09-28 IL IL254783A patent/IL254783B/en active IP Right Grant
- 2017-09-29 PH PH12017501806A patent/PH12017501806A1/en unknown
- 2017-10-02 CL CL2017002474A patent/CL2017002474A1/es unknown
- 2017-11-02 CO CONC2017/0011284A patent/CO2017011284A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018510195A5 (https=) | ||
| ES2423505T3 (es) | Combinación antihelmíntica | |
| ES2246282T3 (es) | El uso de glicirricina para tratar mastitis. | |
| US9289380B2 (en) | Long acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound | |
| RU2017138118A (ru) | Комбинации противоглистных агентов и способы их применения | |
| RU2016133168A (ru) | Изоксазолиновые композиции и их применение в качестве противопаразитарных средств | |
| JP2010535231A (ja) | 内部寄生虫駆除局所組成物 | |
| JP2003113001A (ja) | 内部寄生虫駆除性ゲル組成物 | |
| US20130210755A1 (en) | Methods for inhibiting insect infestations | |
| RU2426550C1 (ru) | Способ лечения телязиозов животных | |
| US9913824B2 (en) | Methods for internally controlling or treating equine bot larvae | |
| EP2744495B1 (en) | Anthelmintic formulations and treatments | |
| MX2008007773A (es) | Composicion veterinaria que comprende una sal organica de levamisol en combinacion con por lo menos una avermectina y/o milbemicina. | |
| RU2629600C1 (ru) | Препарат для лечения паразитозов мелких домашних животных | |
| RU2592236C1 (ru) | Способ лечения и профилактики нематодозов овец | |
| CA2343452A1 (en) | Method of treating a parasitic infection | |
| Jayant et al. | Potential Applications of Ivermectin (IVM) in Dermatology | |
| AU2014332597A1 (en) | Veterinary formulations and methods | |
| ES2436249B1 (es) | Composición antiparasitaria para el control y tratamiento de parásitos de diferentes especies animales, caracterizada por combinar Moxidectina con las vitaminas: A, D3, y E | |
| CN106924232A (zh) | 兽用莫奈太尔复方制剂及其应用 | |
| Shen et al. | The Efficacy Of Milbemycin Oxime In The Treatment Of Naturally Acquired Infestations Of Sarcoptes Scabiei On Dogs | |
| AU2003236560A1 (en) | Worming formulation | |
| US20010036922A1 (en) | Method of treating a parasitic infection | |
| Ostertagia | Persistent Efficacies of Doramectin and Ivermectin in Arkansas Stocker Calves | |
| PAUL et al. | IVERMECTIN: A PROMISING THERAPEUTIC WEAPON TO COMBAT PARASITIC INFECTIONS |